 WALTHAM, Mass., Jan. 06, 2022 GLOBE NEWSWIRE -- Adagio Therapeutics, Inc., Nasdaq: ADGI a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced that Tillman Gerngross, Ph.D., chief executive officer of Adagio, is scheduled to present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 7:30 a.m. ET. 